Harper Molly's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 29, 2024
- Accession no.
- 0001161697-24-000491
- Filed
- Nov 29, 2024
- Trade date
- Nov 27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $385.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harper MollyCIK 0001871470 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 27, 2024 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +17,500 | $5.78 | +$101,150 | 17,500 | Direct | |
| Nov 27, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −17,500 | $22.00 | −$385,000 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 27, 2024 | Common Stock | MOption exerciseDisposed | −17,500 | $0.00 | $0 | 134,020 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.